These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31512997)

  • 1. GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery.
    Gupta MK; Vasudevan NT
    Curr Top Med Chem; 2019; 19(16):1436-1444. PubMed ID: 31512997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Remodeling of the Insulin Receptor Pathway by Thiazolidinediones in Type 2 Diabetes Mellitus: A Brief Review.
    Sahajpal NS; Jain SK
    Protein Pept Lett; 2016; 23(9):836-47. PubMed ID: 27397605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
    Defossa E; Wagner M
    Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
    Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
    Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.
    Rozengurt E; Sinnett-Smith J; Kisfalvi K
    Clin Cancer Res; 2010 May; 16(9):2505-11. PubMed ID: 20388847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty acid receptors as new therapeutic targets for diabetes.
    Rayasam GV; Tulasi VK; Davis JA; Bansal VS
    Expert Opin Ther Targets; 2007 May; 11(5):661-71. PubMed ID: 17465724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G protein-coupled receptors as targets for anti-diabetic therapeutics.
    Oh DY; Olefsky JM
    Nat Rev Drug Discov; 2016 Mar; 15(3):161-72. PubMed ID: 26822831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin sensitization via partial agonism of PPARγ and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats.
    Gandhi GR; Stalin A; Balakrishna K; Ignacimuthu S; Paulraj MG; Vishal R
    Biochim Biophys Acta; 2013 Jan; 1830(1):2243-55. PubMed ID: 23104384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
    Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
    Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule activators of the insulin receptor: potential new therapeutic agents for the treatment of diabetes mellitus.
    Laborde E; Manchem VP
    Curr Med Chem; 2002 Dec; 9(24):2231-42. PubMed ID: 12470244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current anti-diabetic agents and their molecular targets: A review.
    Kerru N; Singh-Pillay A; Awolade P; Singh P
    Eur J Med Chem; 2018 May; 152():436-488. PubMed ID: 29751237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.
    Hansen JB; Arkhammar PO; Bodvarsdottir TB; Wahl P
    Curr Med Chem; 2004 Jun; 11(12):1595-615. PubMed ID: 15180566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally efficacious novel small molecule 6-chloro-6-deoxy-1,2,3,4-tetra-O-galloyl-α-D-glucopyranose selectively and potently stimulates insulin receptor and alleviates diabetes.
    Cao Y; Li Y; Kim J; Ren Y; Himmeldirk K; Liu Y; Qian Y; Liu F; Chen X
    J Mol Endocrinol; 2013; 51(1):15-26. PubMed ID: 23549408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.